Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of tucatinib plus trastuzumab in previously treated HER2-altered advanced solid tumors
jRCT2031210113Phase 2Active, not recruiting
- Sponsor
- Seagen Inc.
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of tucatinib, trastuzumab and fulvestrant in Cervical Cancer (CC), uterine cancer, biliary cancer and 4 more (2 arms), sponsored by Seagen Inc. Primary endpoint: Confirmed objective response rate. Started Jul 2021; status: active, not recruiting.
02
Drugs
03
Conditions
Cervical Cancer (CC)uterine cancerbiliary cancertransitional cell carcinoma (TCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031210113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210113.